# Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

> **NCT02966821** · PHASE2 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 39 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Surufatinib

## Key facts

- **NCT ID:** NCT02966821
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-03
- **Primary completion:** 2018-08-17
- **Final completion:** 2018-11-30
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966821, "Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02966821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*